Short description
Film-coated tablets containing 75 mg / 15.2 mg of acetylsalicylic acid and magnesium hydroxide, respectively: film-coated tablets, white in the shape of a stylized "heart". Film-coated tablets containing 150 mg / 30.39 mg of acetylsalicylic acid and magnesium hydroxide, respectively: film-coated tablets, white, oval in shape with a line on one side.

pharmachologic effect
NSAIDs, antiplatelet agent. The mechanism of action of acetylsalicylic acid is based on irreversible inhibition of the COX-1 enzyme, as a result of which the synthesis of thromboxane A is blocked and platelet aggregation is suppressed. It is believed that acetylsalicylic acid has other mechanisms for suppressing platelet aggregation, which expands the scope of its application in various vascular diseases. Acetylsalicylic acid also has anti-inflammatory, analgesic and antipyretic effects. Magnesium hydroxide, which is part of Cardiomagnyl, protects the gastrointestinal mucosa from the effects of acetylsalicylic acid.

Indications
Primary prevention of cardiovascular diseases such as thrombosis and acute heart failure in the presence of risk factors (for example, diabetes mellitus, hyperlipidemia, arterial hypertension, obesity, smoking, old age). Prevention of recurrent myocardial infarction and blood vessel thrombosis. Prevention of thromboembolism after vascular surgery (coronary artery bypass grafting, percutaneous transluminal coronary angioplasty). Unstable angina.

Method of administration and dosage
The tablets are swallowed whole with water. If desired, the tablet can be broken in half, chewed or pre-ground. Primary prevention of cardiovascular diseases such as thrombosis and acute heart failure in the presence of risk factors (for example, diabetes mellitus, hyperlipidemia, arterial hypertension, obesity, smoking, old age) 1 tablet of Cardiomagnyl containing ASA at a dose of 150 mg on the first day, then 1 tablet of Cardiomagnyl containing ASA at a dose of 75 mg 1 time per day. Prevention of recurrent myocardial infarction and blood vessel thrombosis 1 tablet of Cardiomagnyl containing ASA at a dose of 75-150 mg 1 time per day. Prevention of thromboembolism after vascular surgery (coronary artery bypass grafting, percutaneous transluminal coronary angioplasty) 1 tablet of Cardiomagnyl containing ASA at a dose of 75-150 mg once a day. Unstable angina pectoris 1 tablet of Cardiomagnyl containing ASA at a dose of 75-150 mg once a day.

Side effects
The frequency of the adverse reactions listed below was determined according to the following: very often? 1/10; often 1/100, 1/10; sometimes 1/1000, 1/100; rarely 1/10 000, 1/1000; very rarely 1/10 000, including individual messages. Allergic reactions: urticaria (often), Quincke's edema (often). Immune system: anaphylactic reactions (sometimes). Gastrointestinal tract: nausea (common), heartburn (very common), vomiting (common), pain in the abdomen, ulcers of the gastric and duodenal mucosa (sometimes), including perforation (rare), gastrointestinal bleeding (sometimes), increased activity of? hepatic? enzymes (rare), stomatitis (very rare), esophagitis (very rare), erosive lesions of the upper gastrointestinal tract (very rare), strictures (very rare), colitis (very rare), exacerbation of intestinal irritation (very rare). Respiratory system: bronchospasm (often) Hematopoietic system: increased bleeding (very common), anemia (rare), hypoprothrombinemia (very rare), thrombocytopenia (very rare), neutropenia, aplastic anemia (very rare), eosinophilia (very rare), agranulocytosis (rarely). Central nervous system: dizziness (sometimes), headache (often), insomnia (often), drowsiness (sometimes), tinnitus, intracerebral hemorrhage (rare).

Contraindications
Hypersensitivity to ASA, excipients of the drug and other NSAIDs, cerebral hemorrhage; bleeding tendency (vitamin K deficiency, thrombocytopenia, hemorrhagic diathesis); bronchial asthma induced by the intake of salicylates and NSAIDs; erosive and ulcerative lesions of the gastrointestinal tract (in the acute phase); gastrointestinal bleeding; severe renal failure (creatinine clearance less than 10 ml / min.); pregnancy (I and III trimesters); lactation period; deficiency of glucose-6-phosphate dehydrogenase; simultaneous reception with methotrexate (more than 15 mg per week); children under 18 years of age.

Overdose
Overdose symptoms of moderate severity: nausea, vomiting, tinnitus, hearing impairment, dizziness, confusion. Treatment: the stomach should be flushed, activated charcoal should be prescribed, symptomatic therapy should be carried out. Severe overdose symptoms